Previous 10 | Next 10 |
home / stock / bmy / bmy articles
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
BALA CYNWYD, Pa., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and...
H.C. Wainwright analyst Raghuram Selvaraju downgraded Karuna Therapeutics, Inc. (NASDAQ: KRTX) to Neutral from Buy, raising the...
SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the boar...
Bristol Myers Squibb & Co (NYSE: BMY) has agreed to acquire RayzeBio Inc (NASDAQ: RYZB) for $62.50 per share in cash, for a tota...
Transaction Brings RayzeBio's Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Developmen...
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index turning lower on Friday. The Dow traded down 0.05% to 37,385.32 w...
Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results. AAR reported ...
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 50 points on Friday. The Dow traded up 0.16% to 37,465.58...
News, Short Squeeze, Breakout and More Instantly...
Bristol-Myers Squibb Company Company Name:
BMY Stock Symbol:
NYSE Market:
Bristol-Myers Squibb Company Website:
NORTHAMPTON, MA / ACCESSWIRE / July 22, 2024 / Bristol Myers Squibb Company Our Approach to ESG At BMS, we understand that the future of our company, employees, communities, and the planet are inextricably linked. Our passion for making an impact extends beyond the discovery, development a...
The Application is based on Phase 3 CheckMate - 9DW trial results demonstrating improved survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population Bristol Myers Squibb (NYSE: ...
SBTi validation affirms BMS' long-standing commitment to environmental stewardship PRINCETON, NJ / ACCESSWIRE / July 18, 2024 / Bristol Myers Squibb (NYSE:BMY) today announced validation for its near-term and net-zero science-based targets from the Science Based Targets initiative (SBTi), ...